Lingnau K - Search Results

1

The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.

Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K. Riedl K, et al. Among authors: lingnau k. Vaccine. 2008 Jun 25;26(27-28):3461-8. doi: 10.1016/j.vaccine.2008.04.029. Epub 2008 May 5. Vaccine. 2008. PMID: 18495302

2

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses.

Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, Ginzler M, Swatosch G, Zauner W, Kast C, Akira S, von Gabain A, Buschle M, Lingnau K. Schellack C, et al. Among authors: lingnau k. Vaccine. 2006 Jun 29;24(26):5461-72. doi: 10.1016/j.vaccine.2006.03.071. Epub 2006 Apr 7. Vaccine. 2006. PMID: 16678312

3

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems.

Lingnau K, Riedl K, von Gabain A. Lingnau K, et al. Expert Rev Vaccines. 2007 Oct;6(5):741-6. doi: 10.1586/14760584.6.5.741. Expert Rev Vaccines. 2007. PMID: 17931154 Free article. Review.

4

Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity.

Prchal M, Pilz A, Simma O, Lingnau K, von Gabain A, Strobl B, Müller M, Decker T. Prchal M, et al. Among authors: lingnau k. Vaccine. 2009 Dec 30;27 Suppl 6:G17-20. doi: 10.1016/j.vaccine.2009.10.016. Vaccine. 2009. PMID: 20006134 Review.

5

Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age.

Schmid P, Selak S, Keller M, Luhan B, Magyarics Z, Seidel S, Schlick P, Reinisch C, Lingnau K, Nagy E, Grubeck-Loebenstein B. Schmid P, et al. Among authors: lingnau k. Vaccine. 2011 May 23;29(23):3982-9. doi: 10.1016/j.vaccine.2011.03.081. Epub 2011 Apr 8. Vaccine. 2011. PMID: 21481328

6

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

Agger EM, Rosenkrands I, Olsen AW, Hatch G, Williams A, Kritsch C, Lingnau K, von Gabain A, Andersen CS, Korsholm KS, Andersen P. Agger EM, et al. Among authors: lingnau k. Vaccine. 2006 Jun 29;24(26):5452-60. doi: 10.1016/j.vaccine.2006.03.072. Epub 2006 Apr 17. Vaccine. 2006. PMID: 16675077

7

Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL.

Pilz A, Kratky W, Stockinger S, Simma O, Kalinke U, Lingnau K, von Gabain A, Stoiber D, Sexl V, Kolbe T, Rülicke T, Müller M, Decker T. Pilz A, et al. Among authors: lingnau k. J Immunol. 2009 Aug 15;183(4):2286-93. doi: 10.4049/jimmunol.0901383. Epub 2009 Jul 20. J Immunol. 2009. PMID: 19620292 Free article.

8

Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice.

Olafsdottir TA, Lingnau K, Nagy E, Jonsdottir I. Olafsdottir TA, et al. Among authors: lingnau k. Infect Immun. 2012 Jan;80(1):461-8. doi: 10.1128/IAI.05801-11. Epub 2011 Oct 24. Infect Immun. 2012. PMID: 22025519 Free PMC article.

9

Defined synthetic vaccines.

Zauner W, Lingnau K, Mattner F, von Gabain A, Buschle M. Zauner W, et al. Among authors: lingnau k. Biol Chem. 2001 Apr;382(4):581-95. doi: 10.1515/BC.2001.071. Biol Chem. 2001. PMID: 11405222 Review.

10

IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice.

Olafsdottir TA, Lingnau K, Nagy E, Jonsdottir I. Olafsdottir TA, et al. Among authors: lingnau k. Scand J Immunol. 2009 Mar;69(3):194-202. doi: 10.1111/j.1365-3083.2008.02225.x. Scand J Immunol. 2009. PMID: 19281531 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters